The First Cellular-Rejuvenation Trial Has Begun: What ER-100 Is Really Testing

In 2026, “cellular rejuvenation” moved from animal experiments into a first-in-human trial. ER-100 is designed to partially reprogram cells in the retina and optic nerve using three factors known as OSK. Its phase 1 study is recruiting people with open-angle glaucoma or non-arteritic anterior ischaemic optic neuropathy.

This is a milestone for longevity science—and a much narrower experiment than “scientists can now reverse human aging.”

What ER-100 is

Cells acquire epigenetic changes over time: chemical and structural signals that affect which genes are active without rewriting the underlying DNA sequence. Full reprogramming can return a mature cell toward a stem-cell state, which would be dangerous inside a tissue. Partial reprogramming aims to recover some youthful patterns while preserving cell identity.

ER-100 uses a modified adeno-associated virus vector to deliver genetic instructions for OCT4, SOX2 and KLF4—the OSK factors—to retinal ganglion cells. The trial uses a controlled activation period. According to the registry, the therapy does not replace a participant's existing genes, but gene expression and the vector still require years of safety monitoring.

What the phase 1 trial tests

NCT07290244 is a first-in-human, single-dose phase 1 study with an estimated enrolment of up to 18 adults: up to 12 with open-angle glaucoma and six with NAION. The first question is safety and tolerability, not whether healthy people become biologically younger.

The design starts with dose escalation in glaucoma. A sentinel participant at each new level is observed before an independent safety board allows more participants to receive it. A later expansion evaluates NAION. Participants are followed for up to five years.

The registry lists an actual study start of 2 March 2026, recruiting status and no posted results. Life Biosciences announced the first participant was dosed in June. A first dose proves that a trial has begun; it does not prove efficacy.

Why the eye is the starting point

The eye is accessible to imaging, visual-function testing and local delivery. Researchers can examine retinal structure repeatedly without a tissue biopsy. Treating one eye-related system also limits exposure compared with sending a vector throughout the body.

That makes optic neuropathy a logical test bed. It also means any future benefit would apply first to damaged retinal ganglion cells and vision—not muscles, skin, memory or total lifespan.

The safety questions are substantial

Reprogramming factors change gene activity. Researchers must watch for inflammation, vector-related immune responses, incorrect cell states, uncontrolled growth and loss of normal retinal function. The long follow-up reflects the possibility of delayed effects.

Control is central. The protocol activates OSK for a defined period rather than leaving it continuously on. Preclinical work must still translate across species, disease stages and older human tissue.

Visual improvement would also need careful interpretation. Phase 1 studies are small and may lack a control group. A change from baseline can reflect measurement variability, learning on vision tests or natural fluctuation. Later controlled trials would be needed to establish benefit.

What “younger cells” should mean

Epigenetic clocks and molecular markers can indicate a shift toward a younger pattern, but a biomarker is not automatically a clinical outcome. For a person with optic-nerve disease, useful evidence would include preserved or improved visual fields, retinal structure and daily function, with acceptable risk.

The strongest future claim would connect mechanism to patient benefit: OSK changes the intended cellular programme, retinal cells recover function and vision improves more than in an appropriate comparison group.

The verdict

ER-100 is the first human test of a therapy explicitly built around partial epigenetic reprogramming. That makes 2026 a real turning point. The registered experiment remains a local, small phase 1 safety study in serious optic-nerve conditions.

It is not a treatment for normal aging, not whole-body rejuvenation and not evidence that a human lifespan can be extended. The right milestone to celebrate is more disciplined: a bold animal result has finally reached the stage where human safety can be measured.